Examination of the molecular target treatment for CD70 in the nasal NK/T cell lymphoma

2016 Fiscal Year Final Research Report

• Project/Area Number: 26462576
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Otorhinolaryngology
• Research Institution: Asahikawa Medical College
• Principal Investigator: Kishibe Kan 旭川医科大学, 医学部, 講師 (80447101)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 鼻性NK/T細胞リンパ腫 / 悪性リンパ腫 / CD70 / EBV / 抗体療法

Outline of Final Research Achievements

I investigated a murine xenograft in vivo model, using NOD/Shi-scid/IL-2Rγ null (NOG) mice inoculated subcutaneously with SNK-6 that was established from primary site of the nasal NK/T cell lymphoma (NNKTL). Tumor formation at the inoculated site was detectable in all of the NOG mice. Histologically, the tumor was formed by atypical lymphoid cells that were positive for EBER and CD56. These characteristics were similar to those of the malignant cells that form the tumor tissue of NNKTL patients. Immunohistological staining was performed to analyze CD70 expression in formalin-fixed, paraffin-embedded tissue sections prepared from the subcutaneous tumor. These neoplastic cells clearly expressed CD70. These results suggest that not only cultured SNK-6 cells but also the SNK-6 tumor in the in vivo xenograft model could express CD70.

Free Research Field

腫瘍学